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ABSTRACT
Objective: To investigate the temporal dynamics of cerebral small vessel disease (SVD) by 3 con-
secutive assessments over a period of 9 years, distinguishing progression from regression.
Methods: Changes in SVD markers of 276 participants of the Radboud University Nijmegen Dif-
fusion Tensor and Magnetic Resonance Imaging Cohort (RUN DMC) cohort were assessed at
3 time points over 9 years. We assessed white matter hyperintensities (WMH) volume by semiau-
tomatic segmentation and rated lacunes and microbleeds manually. We categorized baseline
WMH severity as mild, moderate, or severe according to the modified Fazekas scale. We per-
formed mixed-effects regression analysis including a quadratic term for increasing age.
Results: Mean WMH progression over 9 years was 4.7 mL (0.54 mL/y; interquartile range
0.95–5.5 mL), 20.3% of patients had incident lacunes (2.3%/y), and 18.9% had incident micro-
bleeds (2.2%/y). WMH volume declined in 9.4% of the participants during the first follow-up
interval, but only for 1 participant (0.4%) throughout the whole follow-up. Lacunes disappeared
in 3.6% and microbleeds in 5.7% of the participants. WMH progression accelerated over time:
including a quadratic term for increasing age during follow-up significantly improved the model
(p , 0.001). SVD progression was predominantly seen in participants with moderate to severe
WMH at baseline compared to those with mild WMH (odds ratio [OR] 35.5, 95% confidence
interval [CI] 15.8–80.0, p , 0.001 for WMH progression; OR 5.7, 95% CI 2.8–11.2, p ,
0.001 for incident lacunes; and OR 2.9, 95% CI 1.4–5.9, p 5 0.003 for incident microbleeds).
Conclusions: SVD progression is nonlinear, accelerating over time, and a highly dynamic process,
with progression interrupted by reduction in some, in a population that on average shows
progression. Neurology® 2017;89:1569–1577
GLOSSARY
AIC 5 Akaike information criterion; CSFV 5 CSF volume; FLAIR 5 fluid-attenuated inversion recovery; GM 5 gray matter;
GMV 5 gray matter volume; ICV 5 intracranial volume; IQR 5 interquartile range; MMSE 5Mini-Mental State Examination;
MPRAGE 5 magnetization-prepared rapid gradient echo; STRIVE 5 Standards for Reporting Vascular Changes on Neuro-
imaging; SVD 5 small vessel disease; TBV 5 total brain volume;WM 5 white matter;WMH 5 white matter hyperintensities;
WMV 5 white matter volume.
Markers of cerebral small vessel disease (SVD) are present on neuroimaging in virtually every
individual over 60 years of age. They include white matter hyperintensities (WMH), lacunes,
and cerebral microbleeds.1 SVD, and its progression, has been recognized as the most important
vascular contributor to dementia.2,3 Therefore, understanding of the time course of SVD pro-
gression will result in better understanding of both etiology and consequences of SVD.
Current knowledge regarding temporal dynamics of SVD is limited due to lack of studies
with more than one follow-up assessment. Consequently, these studies could only report the
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average, presumably linear change in SVD
severity.4–11 Previous studies, however, have
suggested that SVD progression may be a non-
linear process accelerating over time.12,13
Recent studies suggest that SVD might exert
its clinical effects by affecting remote brain
structure and function.14,15 The temporal rela-
tion between changes in SVD and the subse-
quent atrophy of these remote brain structures
is thus far unknown.
Recently, decrease of WMH volume12,13,16–18
as well as decrease in number of lacunes19,20 and
microbleeds21,22 have been reported, further
challenging the assumption of linear progression
of SVD markers. Neither the time course nor
the magnitude of this disappearing SVD has
been investigated.
In this study, we investigated the temporal
dynamics of SVD by 3 consecutive neuroi-
maging assessments over a period of 9 years
in participants with SVD, distinguishing pro-
gression from regression. As secondary analy-
sis, we investigated the temporal dynamics
related to atrophy of remote brain structures.
METHODS Study population. This study is part of the Rad-
boud University Nijmegen Diffusion Tensor and Magnetic Res-
onance Imaging Cohort (RUNDMC) study, which prospectively
investigates risk factors and clinical consequences of SVD. The
detailed study protocol has been published previously.23 Of 503
baseline participants, 281 underwent repeated MRI assessment at
3 time points. Five participants were excluded because of insuf-
ficient scan quality, yielding a final sample of 276 participants for
the present study (figure e-1 at Neurology.org).
Standard protocol approvals, registrations, and patient
consents. The Medical Review Ethics Committee Region
Arnhem-Nijmegen approved the study and all participants gave
written informed consent.
MRI protocol. Images were acquired at 3 time points on 1.5T
MRI (2006: Siemens [Munich, Germany], Magnetom Sonata;
2011 and 2015: Siemens, Magnetom Avanto) and included the
following whole brain scans: 3D T1 magnetization-prepared
rapid gradient echo (MPRAGE) imaging (voxel size 1.0 3 1.0
3 1.0 mm); fluid-attenuated inversion recovery (FLAIR) pulse
sequences (baseline: voxel size 1.23 1.03 5.0 mm, interslice gap
1.0 mm; follow-up: voxel size 1.23 1.03 2.5 mm; interslice gap
0.5 mm); and a transversal T2*-weighted gradient echo sequence
(voxel size 1.3 3 1.0 3 5.0 mm, interslice gap 1.0 mm). Full
acquisition details have been described previously.23 The same
head coil was used at all 3 time points.
To minimize effects of changes in FLAIR sequence, we re-
sliced follow-up FLAIR images to match slice thickness of base-
line images using linear interpolation.
Brain volumetry. Gray matter (GM), white matter (WM), and
CSF probability maps were computed using SPM12 (fil.ion.ucl.
ac.uk/spm/) unified segmentation routines on the T1 MPRAGE
images. In addition, we used the WMH masks to correct the
segmentation images, since several brain regions with WMH
damage were initially misclassified. All WMH voxels were given
mean WM intensity and these corrected T1 images were seg-
mented using SPM12. All images were visually checked for cor-
egistration and segmentation artefacts. GM volumes (GMV),
WM volumes (WMV), and CSF volumes (CSFV) were com-
puted by summing all voxels belonging to that tissue class mul-
tiplied by voxel volume in mL. Intracranial volume (ICV) was
determined by summing GMV, WMV, and CSFV and total
brain volume (TBV) by summing GMV and WMV.
To account for interscan effects, we corrected for differences
in ICV between baseline and follow-up. We normalized all vol-
umes to baseline ICV to account for head size.24
Small vessel disease. SVD was rated according to the Standards
for Reporting Vascular Changes on Neuroimaging (STRIVE) cri-
teria.1 WMH volumes were calculated by a semiautomatic WMH
segmentation method, which has been described in detail else-
where.25 Segmentations were visually checked for segmentation
errors by one trained rater, blinded for clinical data. WMH vol-
umes were corrected for interscan differences in ICV and then
normalized to baseline ICV. We also calculated WMH volumes
for odd and even slices separately to determine the effects of
change in slice thickness of the FLAIR sequence.
We used the modified Fazekas scale to categorize WMH
severity at baseline (mild: Fazekas 0–1; moderate: Fazekas 2;
severe: Fazekas 3).26
Both number and location of lacunes and microbleeds were
rated manually on FLAIR/T1-weighted and T2*-weighted MRI
scans according to the STRIVE criteria1 by 2 trained raters blinded
for clinical data. Follow-up FLAIR images were resliced to match
the baseline scans to prevent differences in partial volume effects
between baseline and follow-up scans. Interrater and intrarater
reliability were excellent.27 Incidence was expressed as number of
participants with new lacunes or microbleeds. We identified
whether lacunes or microbleeds were truly incident or disappeared
and in which time period. To minimize risk of misclassification due
to coregistrations, we visually inspected all WMH segmentations
and corrected lacune occurrence maps based on manual ratings.
Vascular risk factors. We assessed presence of hypertension,
smoking, alcohol use, body mass index, diabetes, and hypercho-
lesterolemia by standardized questionnaires, as described
previously.23
Statistical analysis. We calculated differences in baseline char-
acteristics between participants and those without follow-up
using univariate analyses. Differences in Mini-Mental State
Examination (MMSE) score between individuals with mild vs
moderate or severe WMH at baseline and with or without WMH
progression were examined using nonparametric tests.
We created WMH probability maps and distribution maps of
lacunes. WMH decline was defined as more than 0.25 mL vol-
ume decline, as this was shown to be the smallest change that
could be confirmed visually.15 We plotted change of WMH vol-
umes by age at individual level using R package ggplot2 (version
2.1.0).28 R package lme4 was used to perform linear mixed-effects
regression analysis to analyze WMH change as function of base-
line age and time (version 1.1-12).29 We used a random intercept
and random slope model, which permits the estimation of an
average slope across the whole cohort while allowing for interin-
dividual variability. By smoothed curves using loess smoothing
we explored average WMH change with increasing age. To eval-
uate a possible quadratic relationship, indicating nonlinear pro-
gression of SVD, we compared model fit between the full model
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and the full model with a quadratic term for increasing age during
follow-up included using a likelihood ratio test, and we evaluated
change in Akaike information criterion (AIC).
To determine remote effects of SVD progression, we analyzed
the relation between WMH progression in the first follow-up
interval and subsequent brain atrophy by means of linear regres-
sion analysis. Multicollinearity between different SVD markers
was investigated using regression analysis.
To identify differences in vascular risk factors in individuals
with regression of SVD markers, we compared vascular risk fac-
tors for participants with and without regression of SVD markers
and with those who remained relatively stable by analysis of var-
iance followed by Bonferroni correction.
We created WMH probability maps stratified by baseline age
and by baseline WMH severity. We repeated mixed-effects regres-
sion analysis stratified by baseline WMH severity to explore
change in WMH within these groups separately. We calculated
odds of SVD progression according to baseline Fazekas 0–1 vs
Fazekas 2–3 by logistic regression analysis, adjusted for age and sex.
Statistical analyses were performed using SPSS Statistics ver-
sion 20 and R Programming Language version 3.2.1.
RESULTS Baseline characteristics are presented in
table 1. Mean age at baseline was 62.5 6 7.7 years
and 59.1% were male. Mean follow-up duration was
5.4 6 0.2 years until first and 8.7 6 0.2 years until
second follow-up. Participants with moderate to
severe WMH at baseline had lower MMSE scores
(27.7 6 1.7 vs 28.4 6 1.5; p , 0.001) compared to
participants with mild WMH. Steeper decline in
MMSE score was seen in participants with WMH
progression compared to participants whose WMH
remained relatively stable (20.95 6 2.5 vs 20.32 6
1.8; p 5 0.031). Those lost to follow-up were sig-
nificantly older and had more severe baseline SVD
characteristics compared to participants (table e-1).
Temporal dynamics of SVD. WMH probability maps
are shown in figure e-2 and video 1. Mean WMH
progression was 0.54 mL/y (median 0.24; interquar-
tile range [IQR] 0.11–0.64 mL/y). Progression of
WMH increased with baseline age (figure 1, A and B;
video 2). In mixed-effects regression analysis, each
year increase of age at baseline resulted in an increase
in WMH as percentage of WM of 0.10% (95% CI
0.07%–13.7%). Including a quadratic term for
increasing age during follow-up significantly
improved the model (AIC base model 2995.2 vs AIC
extended model 2932.9, likelihood ratio test, x2 5
64.3, df5 1, p, 0.001). Severity and progression of
WMH were comparable for men and women.
Table 1 Demographic and imaging characteristics
Baseline
(2006),
n 5 276
Follow-up 1
(2011),
n 5 276
Follow-up 2
(2015),
n 5 276
Change
(2006–2011)
Change
(2011–2015)
Overall change
(2006–2015)
Demographics
Age, y, mean (SD) 62.5 (7.7) 67.8 (7.7) 71.2 (7.8) 5.3 (0.2) 3.4 (0.2) 8.7 (0.2)
Time until follow-up, y, mean (SD) — 5.4 (0.2) 8.7 (0.2) — — —
Sex, male, n (%) 163 (59.1) — — — — —
Education >primary school, n (%) 259 (93.8) — — — — —
MMSE score, mean (SD) 28.6 (1.3) 28.4 (1.8) 28.2 (2.0) 20.23 (1.7) 20.22 (1.6) 20.45 (2.0)
SVD characteristics
White matter hyperintensities, mL,
median (IQR)
2.3 (0.8–6.1) 2.8 (1.2–7.7) 4.7 (2.0–11.5) 0.52 (0.03–1.6) 1.5 (0.51–3.8) 2.1 (0.95–5.5)
White matter hyperintensities, mL,
mean (SD)
5.8 (9.5) 7.4 (11.5) 10.5 (14.4) 1.6 (3.6) 3.1 (4.3) 4.7 (6.6)
% WMH of WM, mean (SD) 1.3 (2.3) 1.7 (2.9) 2.5 (3.8) 0.42 (1.0) 0.79 (1.2) 1.2 (1.9)
Participants with any lacunes, n (%) 55 (19.9) 70 (25.4) 77 (27.9) 15 (5.4) 7 (2.5) 22 (8.0)
Total no. of lacunes 117 165 203 48 38 86
Participants with any microbleeds, n (%)a 36 (13.6) 49 (18.5) 66 (24.9) 13 (4.9) 17 (6.4) 30 (11.4)
Total no. of microbleedsa 140 186 219 46 32 79
Participants with any territorial infarcts, n (%) 23 (8.3) 27 (9.8) 29 (10.5) 4 (1.4) 2 (0.7) 6 (2.2)
Brain volumes
White matter volume, mL (SD) 465.6 (38.9) 455.2 (43.8) 444.0 (45.6) 210.5 (13.7) 211.2 (11.9) 221.6 (17.2)
Gray matter volume, mL (SD) 620.7 (48.9) 610.5 (49.8) 598.4 (51.2) 210.2 (16.8) 212.1 (13.5) 222.2 (20.4)
Abbreviations: IQR 5 interquartile range; MMSE 5 Mini-Mental State Examination; SVD 5 small vessel disease; WM 5 white matter; WMH 5 white matter
hyperintensities.
Data shown are unadjusted values and represent n (%), mean (SD), or median (IQR). Change represents the number of participants without lacunes or
microbleeds at baseline who developed lacunes or microbleeds during follow-up.
a For ratings of microbleeds, 12 participants were additionally excluded based on missing T2* or scan artefacts at any time point.
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Fifty-six participants (20.3%) developed new la-
cunes over 9 years (2.3%/y; table 2). The distribution
of lacunes is shown in figure e-2 and video 3. Incidence
of lacunes was higher for the second follow-up period
(3.5%/y) than for the first follow-up period (2.7%/y).
Fifty participants (18.9%) developed new micro-
bleeds over 9 years (2.2%/y) (table 2). Incidence of
microbleeds in the second follow-up period (4.2%/y)
was higher than in the first follow-up period (1.7%/y).
WMH progression in the first follow-up period was
associated with brain atrophy in the second follow-up
period (b 5 0.124; p 5 0.040) as well as with WM
atrophy (b 5 0.149; p 5 0.013) but not with GM
atrophy (b 5 0.045; p 5 0.461). Multicollinearity
between SVD markers is shown in table e-2.
Regression of SVD markers. We also observed regres-
sion of SVD markers. We observed decline in
WMH volume in 26 participants (9.4%; median
decline 20.5 mL; IQR 20.9 to 20.3 mL) during
the first follow-up period and in 5 participants (1.8%;
median 20.5 mL; IQR 20.9 to 20.4 mL) during
the second follow-up period. In one participant,
WMH volume declined over the course of 9 years
(0.4%; 20.4 mL). In 10 participants (3.6%), 14 la-
cunes could not be found at follow-up imaging (table
2). In 15 participants (5.7%), 37 microbleeds were no
longer detectable after 9 years of follow-up (table 2).
Examples of lacunes and microbleeds that were no
longer visible on follow-up imaging are shown in
figure 2. There were no differences for any of the
Figure 1 Temporal dynamics of white matter hyperintensities (WMH) progression
(A) Change inWMH volume (mL) over 3 time points by age at individual level. (B) Acceleration ofWMH volume change over 2 follow-up periods (mL/y) by age at
individual level. (C) Change in WMH volume (mL) over 3 time points by age at individual level stratified by baseline WMH severity. Baseline WMH severity was
classified as mild (Fazekas 0–1; n 5 211), moderate (Fazekas 2; n 5 33), or severe (Fazekas 3; n 5 20). Smoothed curves using loess smoothing express
average WMH change with increasing age.
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vascular risk factors between participants with and
without regression of SVD markers, also compared
with those who remained relatively stable over the 9-
year course (data not shown).
Heterogeneity in temporal dynamics of SVD. Mean
WMH progression over 9 years was 2.4 mL for par-
ticipants with mild WMH at baseline, 12.0 mL for
those with moderate WMH, and 15.2 mL for those
with severe WMH (figures 1C and 3 and video 4).
From participants with mild WMH at baseline, 6%
showed WMH progression beyond measurement
error, compared with 75% of participants with mod-
erate or severe WMH. Participants with moderate to
severe WMH at baseline had 36 times higher risk of
WMH progression compared to participants with
mild WMH (OR 35.5, 95% CI 15.8–80.0; p ,
0.001). Participants with moderate to severe WMH
also more often developed incident lacunes (OR 5.7,
95% CI 2.8–11.2; p , 0.001) and microbleeds (OR
2.9, 95% CI 1.4–5.9; p 5 0.003) compared to par-
ticipants with mild WMH at baseline.
DISCUSSION In this study, we showed the tempo-
ral dynamics of SVD, revealing both SVD progres-
sion and regression, using 3 imaging assessments
over a period of 9 years. We demonstrated that pro-
gression of all SVD markers occurred in a nonlinear
fashion, accelerating over time consistent with
a quadratic course. In addition, we showed that
participants with moderate or severe WMH had
a high likelihood of progression of their SVD,
whereas participants with mild baseline SVD
showed mild progression over a period of 9 years.
Our study demonstrates that SVD progression is
not linear but accelerates with increasing age. While
the average progression in our study is comparable
with other studies,4–11 the use of 3 imaging assess-
ments allowed us to show that SVD progression
accelerated over time, providing evidence for a non-
linear process.12,13 Moreover, our results suggest
that a quadratic course of SVD progression over
time is plausible, since including a quadratic term
improved the model. Although we would need more
than 3 time points to further study exponential
functions, our study indicates nonlinear temporal
dynamics of SVD progression. Our findings do
not support the hypothesized ceiling effect in which
WMH progression reaches a certain threshold at
high age and high lesion volume,2 as we also saw
WMH progression in those at high age and with
high SVD lesion load.
The relation between WMH progression and sub-
sequent WM atrophy and TBV atrophy suggests that
SVD affects adjacent brain structures. WM atrophy
Table 2 Lacunes and microbleeds per brain location
Lacunes Microbleeds
Baseline
(2006),
n 5 276
Follow-up 1
(2011),
n 5 276
Follow-up 2
(2015),
n 5 276 Incident Disappearing
Baseline
(2006),
n 5 264
Follow-up 1
(2011),
n 5 264
Follow-up 2
(2015),
n 5 264 Incident Disappearing
Subcortical
Frontal 22 (8.0) 27 (9.8) 31 (11.2) 18 (6.5) 3 (1.1) 18 (6.8) 21 (7.9) 27 (10.2) 20 (7.6) 6 (2.3)
Parietal 9 (3.3) 10 (3.6) 10 (3.6) 3 (1.1) 2 (0.7) 8 (3.0) 10 (3.8) 19 (7.2) 17 (6.5) 2 (0.8)
Occipital 1 (0.4) 1 (0.4) 1 (0.4) 0 (0.0) 1 (0.4) 8 (3.0) 9 (3.4) 9 (3.4) 4 (1.5) 4 (1.5)
Temporal 9 (3.3) 9 (3.3) 11 (4.0) 3 (1.1) 0 (0.0) 11 (4.2) 12 (4.5) 15 (5.7) 8 (3.1) 5 (2.0)
Any
subcortical
31 (11.2) 34 (12.3) 40 (14.5) 21 (7.6) 6 (2.2) 30 (11.3) 35 (13.2) 49 (18.5) 36 (13.6) 14 (5.3)
Deep
Basal gangliaa 25 (9.1) 39 (14.1) 46 (16.7) 35 (12.7) 5 (1.8) 9 (3.4) 15 (5.7) 17 (6.4) 11 (4.2) 1 (0.4)
Thalamus 4 (1.4) 7 (2.5) 10 (3.6) 6 (2.2) 0 (0.0) 4 (1.5) 4 (1.5) 6 (2.3) 3 (1.2) 2 (0.8)
Internal
capsule
4 (1.4) 5 (1.8) 7 (2.5) 3 (1.1) 0 (0.0) 4 (1.5) 4 (1.5) 3 (1.1) 1 (0.4) 2 (0.8)
Any deep 29 (10.5) 44 (15.9) 52 (18.8) 41 (14.9) 5 (1.8) 14 (5.3) 23 (8.7) 30 (11.3) 21 (7.9) 3 (1.1)
Infratentorialb
Any
infratentorial
13 (4.7) 20 (7.2) 21 (7.6) 10 (3.6) 0 (0.0) 5 (1.9) 11 (4.2) 17 (6.4) 12 (4.6) 1 (0.4)
Any 55 (19.9) 70 (25.4) 77 (27.9) 56 (20.3) 10 (3.6) 36 (13.6) 49 (18.5) 66 (24.9) 50 (18.9) 15 (5.7)
Data represent number of participants (%) with lacunes/microbleeds per brain location.
a Basal ganglia includes globus pallidus, putamen, and caudate nucleus.
b Infratentorial includes pons, mesencephalon, medulla oblongata, and cerebellum.
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might be the result of disconnected white matter
tracts due to SVD, leading to axonal loss by anterog-
rade or retrograde degeneration, and subsequently the
loss of brain volume.3,30 The clinical observation that
patients with similar SVD burden show heterogeneity
in clinical symptoms might be explained by discon-
nection of WM tracts.
Imaging assessments at 3 time points also enabled
us to identify regression of SVD markers followed by
progression, in a cohort that on average showed pro-
gression. This observation provides further evidence
that SVD does not gradually evolve but is a dynamic
process, with progression interrupted by regression
in some. Thus far, few other studies have reported
a decline in WMH volume,12,13,16,17 possibly because
WMH decline within a certain time window was
compensated by WMH progression thereafter (or
vice versa). Two imaging assessments do not allow
disentangling of episodes with regression from those
with progression.
The observed decline in WMHmay have several
explanations. First, WMH decline in the first
follow-up period could be explained in part by par-
tial volume effects caused by slight adjustments in
FLAIR sequences between baseline and first
follow-up. However, this is unlikely because
WMH volumes calculated from even and odd slices
were identical and because we also found WMH
decline between the second and third MRI assess-
ment. Second, different orientation of participants
in the scanner might also partly explain disappear-
ing SVD, especially for smaller lesions. In order to
prevent this, we classified WMH regression as more
than 0.25 mL volume decline. Third, recently
developed WMH might represent areas of tissue
edema. Reduction in tissue edema at a later stage
could lead to reduced WMH volume.16 Fourth,
improved control of vascular risk factors or factors
influencing the blood–brain barrier might play
a role by reducing WMH volume.16,17 Disappear-
ance of lacunes could be due to partial volume
effects, due to collapsing lacunes or to incorpora-
tion of the lacune into the ventricle (figure 2).19,20
Disappearing microbleeds may be explained by
Figure 2 Lacunes and microbleeds no longer visible on follow-up imaging
Examples of a lacune that is no longer detectable on follow-up imaging (A), which appears to be assimilated by the ventricle.
Microbleeds (B) appear to have faded away over time.
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partial volume effects as well as by clearance
of hemosiderin-containing macrophages.22 Our
findings are in line with the latter hypothesis. In
most cases, microbleeds seemed to fade away
between 2006 and 2011 and were no longer visible
in 2015.
All SVD markers at baseline were important pre-
dictors for SVD progression, in a nonlinear way and
independent of age. Additional analyses on progres-
sion of SVD markers by distribution of microbleeds
did not reveal significantly different progression for
participants with strictly lobar compared to partici-
pants with deep microbleeds (data not shown),
although this analysis might have been underpow-
ered. Although we would require an even longer
follow-up to exclude the possibility that all partici-
pants with mild baseline WMH will ultimately
progress to severe WMH, our data show that even
the oldest participants with mild baseline WMH
rarely show progression over a time course of 9 years.
This suggests different progression curves for partici-
pants with mild vs severe baseline WMH, implying
heterogeneity in etiology of mild vs severe SVD.
Small WMH volumes, representing punctuate
WMH or small periventricular caps, probably consist
of enlarged perivascular spaces and subependymal
gliosis.7 On the contrary, confluent WMH represent
a continuum of ischemic tissue damage, ranging from
mild fiber loss to complete infarction, and may have
a more malignant course in terms of cognitive dete-
rioration. These different etiologies call upon a differ-
ent diagnostic and therapeutic approach. The
correlation between WMH severity and progression
and MMSE score underlines the clinical relevance of
Figure 3 White matter hyperintensities (WMH) probability maps stratified by baseline WMH severity
Probabilities of presence of WMH stratified by baselineWMH severity, color-coded in percentage from 5% to 75%. Baseline WMH severity is determined as
mild (Fazekas 0–1; n5 211), moderate (Fazekas 2; n5 33), or severe (Fazekas 3; n5 20). The overall 9-year change is shown in the right column. Probability
maps through the whole brain can be seen in video 4.
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our findings on interindividual variability in SVD
progression.
Strengths of this study include the large cohort of
participants with SVD and the long follow-up dura-
tion. Furthermore, imaging assessments at 3 time
points allowed us to characterize change in SVD over
time, including SVD regression. SVD was rated
according to standardized procedures,1 minimizing
risk of misclassification. Moreover, semiautomatic
WMH quantification reduced risk of information
bias.2 Furthermore, brain volumes were deter-
mined with the newest segmentation routines of
SPM12 and corrected for segmentation errors
using WMH masks. Finally, our study has high
external validity for patients with SVD in a general
neurology clinic.
A limitation of our study is change of MRI scanner
between baseline and first follow-up. However, by
taking into account the third MRI assessment, we
are able to capture most of this possible bias. A slight
adjustment in FLAIR sequence between baseline and
first follow-up may have caused an overestimation of
incident lacunes. However, we limited the possible
negative effects by reslicing follow-up to baseline
FLAIR images before rating lacunes. Besides, changes
in signal characteristics of normal brain tissue and
WMH might have led to artefactually higher rates
of lesion development. However, we considered this
unlikely, since we also observed regression of SVD
markers from the second to third time period in a con-
siderable proportion of participants. Further, due to
low-resolution T2* sequences, we might have missed
smaller microbleeds. However, since similar gradient
echo sequences are applied for all time points, risk of
misclassification will result in comparable systematic
error for all time points. Inevitably, attrition bias may
have occurred due to the very long-term follow-up,
probably leading to an underestimation of progres-
sion of SVD, since those who dropped out were older
and had more severe SVD.
Our study demonstrates that SVD progression is
a nonlinear, dynamic, and highly variable process,
predominantly seen in participants with moderate
or severe WMH at baseline. Equally important, those
with mildWMH rarely show progression over a 9-year
course. Since SVD progression has been linked to cog-
nitive decline and development of dementia, our find-
ings on interindividual variability in SVD progression
might be a major step forward in developing personal-
ized treatment approaches. The finding that progres-
sion of SVD is sometimes interrupted by regression
and that SVD progression occurs in a quadratic way
and hence is not gradually, linearly progressive as was
previously thought suggests a paradigm shift on how
SVD processes should be considered. Future studies
should elaborate on the clinical consequences of this
nonlinear dynamic time course of SVD progression.
AUTHOR CONTRIBUTIONS
Dr. van Leijsen: design and conceptualization of the study; acquisition,
analysis, and interpretation of the data; drafting and revising the manu-
script for intellectual content. Dr. van Uden: design and conceptualiza-
tion of the study; acquisition, analysis, and interpretation of the data;
drafting and revising the manuscript for intellectual content. Dr. Gha-
foorian: analysis and interpretation of the data; revising the manuscript
for intellectual content. Dr. Bergkamp: acquisition, analysis, and interpre-
tation of the data; revising the manuscript for intellectual content. Dr.
Lohner: acquisition and analysis of the data; revising the manuscript
for intellectual content. E.C.M. Kooijmans: acquisition and analysis of
the data; revising the manuscript for intellectual content. Dr. van der
Holst: acquisition and analysis of the data; revising the manuscript for
intellectual content. Dr. Tuladhar: acquisition and analysis of the data;
revising the manuscript for intellectual content. Dr. Norris: design and
conceptualization of the study; revising the manuscript for intellectual
content. Dr. van Dijk: design and conceptualization of the study; revising
the manuscript for intellectual content. Dr. Rutten-Jacobs: analysis and
interpretation of the data; revising the manuscript for intellectual content.
Dr. Platel: analysis and interpretation of the data; revising the manuscript
for intellectual content. Dr. Klijn: design and conceptualization of the
study; interpretation of the data; drafting and revising the manuscript
for intellectual content. Dr. de Leeuw: design and conceptualization of
the study; interpretation of the data; drafting and revising the manuscript
for intellectual content. Statistical analysis was conducted by Drs. van
Leijsen, van Uden, and Rutten-Jacobs.
STUDY FUNDING
No targeted funding reported.
DISCLOSURE
E. van Leijsen, I. van Uden, M. Ghafoorian, M. Bergkamp, V. Lohner,
E. Kooijmans, and H. van der Holst report no disclosures relevant to the
manuscript. A. Tuladhar is a junior staff member of the Dutch Heart
Foundation (grant 2016T044). D. Norris reports no disclosures relevant
to the manuscript. E. van Dijk received a personal fellowship from the
Dutch Brain Foundation (H04-12; F2009[1]-16). L. Rutten-Jacobs is
supported by a British Heart Foundation Immediate Research Fellowship
(FS/15/61/31626). B. Platel reports no disclosures relevant to the manu-
script. C. Klijn is supported by a clinical established investigator grant of
the Dutch Heart Foundation (grant 2012 T077) and an Aspasia
grant from The Netherlands Organisation for Health Research and
Development (ZonMw grant 015.008.048). F. de Leeuw is supported
by a clinical established investigator grant of the Dutch Heart Foundation
(grant 2014 T060), by a VIDI innovational grant from The Netherlands
Organisation for Health Research and Development (ZonMw grant
016.126.351), and the MIRA Institute for Biomedical Technology and
Technical Medicine, University of Twente. Go to Neurology.org for full
disclosures.
Received March 9, 2017. Accepted in final form July 10, 2017.
REFERENCES
1. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging
standards for research into small vessel disease and its con-
tribution to ageing and neurodegeneration. Lancet Neurol
2013;12:822–838.
2. Prins ND, Scheltens P. White matter hyperintensities,
cognitive impairment and dementia: an update. Nat Rev
Neurol 2015;11:157–165.
3. Banerjee G, Wilson D, Jager HR, Werring DJ. Novel
imaging techniques in cerebral small vessel diseases and
vascular cognitive impairment. Biochim Biophys Acta
2016;1862:926–938.
1576 Neurology 89 October 10, 2017
4. Benjamin P, Zeestraten E, Lambert C, et al. Progression of
MRI markers in cerebral small vessel disease: sample size
considerations for clinical trials. J Cereb Blood Flow
Metab 2016;36:228–240.
5. Gouw AA, van der Flier WM, van Straaten EC, et al.
Reliability and sensitivity of visual scales versus volumetry
for evaluating white matter hyperintensity progression.
Cerebrovasc Dis 2008;25:247–253.
6. Maillard P, Crivello F, Dufouil C, Tzourio-Mazoyer N,
Tzourio C, Mazoyer B. Longitudinal follow-up of individual
white matter hyperintensities in a large cohort of elderly.
Neuroradiology 2009;51:209–220.
7. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F;
Austrian Stroke Prevention Study. Progression of cerebral
white matter lesions: 6-year results of the Austrian Stroke
Prevention Study. Lancet 2003;361:2046–2048.
8. Akoudad S, Ikram MA, Koudstaal PJ, et al. Cerebral mi-
crobleeds are associated with the progression of ischemic
vascular lesions. Cerebrovasc Dis 2014;37:382–388.
9. Gouw AA, van der Flier WM, Pantoni L, et al. On the
etiology of incident brain lacunes: longitudinal observa-
tions from the LADIS study. Stroke 2008;39:3083–3085.
10. Ding J, Sigurdsson S, Garcia M, et al. Risk factors associ-
ated with incident cerebral microbleeds according to loca-
tion in older people: the Age, Gene/Environment
Susceptibility (AGES)–Reykjavik study. JAMA Neurol
2015;72:682–688.
11. Klarenbeek P, van Oostenbrugge RJ, Rouhl RP, Knottnerus
IL, Staals J. Higher ambulatory blood pressure relates to new
cerebral microbleeds: 2-year follow-up study in lacunar stroke
patients. Stroke 2013;44:978–983.
12. Ramirez J, McNeely AA, Berezuk C, Gao F, Black SE.
Dynamic progression of white matter hyperintensities in
Alzheimer’s disease and normal aging: results from the
Sunnybrook Dementia Study. Front Aging Neurosci
2016;8:62.
13. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal
PJ, Breteler MM. Progression of cerebral small vessel disease
in relation to risk factors and cognitive consequences:
Rotterdam Scan Study. Stroke 2008;39:2712–2719.
14. Duering M, Righart R, Csanadi E, et al. Incident subcor-
tical infarcts induce focal thinning in connected cortical
regions. Neurology 2012;79:2025–2028.
15. Lambert C, Benjamin P, Zeestraten E, Lawrence AJ, Barrick
TR, Markus HS. Longitudinal patterns of leukoaraiosis and
brain atrophy in symptomatic small vessel disease. Brain
2016;139:1136–1151.
16. Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S.
What are white matter hyperintensities made of?
Relevance to vascular cognitive impairment. J Am Heart
Assoc 2015;4:001140.
17. Cho AH, Kim HR, Kim W, Yang DW. White matter
hyperintensity in ischemic stroke patients: it may regress
over time. J Stroke 2015;17:60–66.
18. Sachdev P, Wen W, Chen X, Brodaty H. Progression of
white matter hyperintensities in elderly individuals over
3 years. Neurology 2007;68:214–222.
19. Okazaki S, Hornberger E, Griebe M, Gass A, Hennerici
MG, Szabo K. MRI characteristics of the evolution of
supratentorial recent small subcortical infarcts. Front Neu-
rol 2015;6:118.
20. Loos CM, Staals J, Wardlaw JM, van Oostenbrugge RJ.
Cavitation of deep lacunar infarcts in patients with first-
ever lacunar stroke: a 2-year follow-up study with MR.
Stroke 2012;43:2245–2247.
21. Poels MM, Ikram MA, van der Lugt A, et al. Incidence of
cerebral microbleeds in the general population: the Rot-
terdam Scan Study. Stroke 2011;42:656–661.
22. Lee SH, Lee ST, Kim BJ, et al. Dynamic temporal change
of cerebral microbleeds: long-term follow-up MRI study.
PLoS One 2011;6:e25930.
23. van Norden AG, de Laat KF, Gons RA, et al. Causes and
consequences of cerebral small vessel disease: The RUN
DMC study: a prospective cohort study: study rationale
and protocol. BMC Neurol 2011;11:29.
24. Colliot O, Chetelat G, Chupin M, et al. Discrimination
between Alzheimer disease, mild cognitive impairment,
and normal aging by using automated segmentation of
the hippocampus. Radiology 2008;248:194–201.
25. Ghafoorian M, Karssemeijer N, van Uden IW, et al.
Automated detection of white matter hyperintensities
of all sizes in cerebral small vessel disease. Med Phys
2016;43:6246.
26. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA.
MR signal abnormalities at 1.5 T in Alzheimer’s dementia
and normal aging. AJR Am J Roentgenol 1987;149:351–356.
27. van Uden IW, Tuladhar AM, van der Holst HM, et al.
Diffusion tensor imaging of the hippocampus predicts the
risk of dementia; the RUN DMC study. Hum Brain
Mapp 2016;37:327–337.
28. Wickham H. ggplot2: Elegant Graphics for Data Analysis.
New York: Springer; 2009.
29. Bates D, Machler M, Bolker BM, Walker SC. Fitting
linear mixed-effects models using lme4. J Stat Softw
2015;67:1–48.
30. Dziedzic T, Metz I, Dallenga T, et al. Wallerian degener-
ation: a major component of early axonal pathology in
multiple sclerosis. Brain Pathol 2010;20:976–985.
Neurology 89 October 10, 2017 1577
